Abstract
Duchenne muscular dystrophy (DMD) is a relatively widespread genetic disease which develops as a result of a mutation in the gene DMD encoding dystrophin. In this review, animal models of DMD are described. These models are used in preclinical studies to elucidate the pathogenesis of the disease or to develop effective treatments; each animal model has its own advantages and disadvantages. For instance, Caenorhabditis elegans, Drosophila melanogaster, and zebrafish (sapje) are suitable for large-scale chemical screening of large numbers of small molecules, but their disease phenotype differs from that of mammals. The use of larger animals is important for understanding of the potential efficacy of various treatments for DMD. While mdx mice have their advantages, they exhibit a milder disease phenotype compared to humans or dogs, making it difficult to evaluate the efficacy of new treatment for DMD. The disease in dogs and pigs is more severe and progresses faster than in mice, but it is more difficult to breed and obtain sufficient numbers of specimens in order to achieve statistically significant results. Moreover, working with large animals is also more labor-intensive. Therefore, when choosing the optimal animal model for research, it is worth considering all the goals and objectives.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aartsma-Rus A, Ginjaar IB, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53:145–151. https://doi.org/10.1136/jmedgenet-2015-103387
Allen DG, Whitehead NP (2010) Duchenne muscular dystrophy–what causes the increased membrane permeability in skeletal muscle? Int J Biochem Cell Biol 43:290–294. https://doi.org/10.1016/j.biocel.2010.11.005
Allen DG, Whitehead NP, Froehner SC (2016) Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev 96:253–305. https://doi.org/10.1152/physrev.00007.2015
Ambrósio CE, Valadares MC, Zucconi E, Cabral R, Pearson PL, Gaiad TP, Canovas M, Vainzof M, Miglino MA, Zatz M (2008) Ringo, a golden retriever muscular dystrophy (GRMD) dog with absent dystrophin but normal strength. Neuromuscul Disord 18:892–893. https://doi.org/10.1016/j.nmd.2008.06.385
Amoasii L, Long C, Li H, Mireault AA, Shelton JM, Sanchez-Ortiz E, McAnally JR, Bhattacharyya S, Schmidt F, Grimm D, Hauschka SD, Bassel-Duby R, Olson EN (2017) Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 9:eaan081. https://doi.org/10.1126/scitranslmed.aan8081
Amoasii L, Li H, Zhang Y, Min YL, Sanchez-Ortiz E, Shelton JM, Long C, Mireault AA, Bhattacharyya S, McAnally JR, Bassel-Duby R, Olson EN (2019) In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse. Nat Commun 10:4537. https://doi.org/10.1038/s41467-019-12335-x
Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18:1995–2005. https://doi.org/10.1038/mt.2010.186
Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S (2012) Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 109:13763–13768. https://doi.org/10.1073/pnas.1204638109
Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T, Takeda S (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22:4914–4928. https://doi.org/10.1093/hmg/ddt341
Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I, Kobayashi T, Katsuki M (1997) Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun 238:492–497. https://doi.org/10.1006/bbrc.1997.7328
Bartlett RJ, Stockinger S, Denis MM, Bartlett WT, Inverardi L, Le TT, Thi Man N, Morris GE, Bogan DJ, Metcalf-Bogan J, Kornegay JN (2000) In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat Biotechnol 18:615–622. https://doi.org/10.1038/76448
Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS (2017) Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 8:14454. https://doi.org/10.1038/ncomms14454
Bessou C, Giugia JB, Franks CJ, Holden-Dye L, Ségalat L (1998) Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission. Neurogenetics 2:61–72. https://doi.org/10.1007/s100480050053
Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36:395–402. https://doi.org/10.1002/humu.22758
Blake D, Tinsley J, Davies K (1996) Utrophin: a structural and functional comparison to dystrophin. Brain Pathol 6:37–47. https://doi.org/10.1111/j.1750-3639.1996.tb00781.x
Bostick B, Yue Y, Long C, Duan D (2008) Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 102:121–130. https://doi.org/10.1161/CIRCRESAHA.107.162982
Bostick B, Yue Y, Long C, Marschalk N, Fine DM, Chen J, Duan D (2009) Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice. Mol Ther 17:253–261. https://doi.org/10.1038/mt.2008.264
Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81:1189–1192. https://doi.org/10.1073/pnas.81.4.1189
Bushby KM, Gardner-Medwin D (1993) The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I Nat Hist J Neurol 240:98–104. https://doi.org/10.1007/BF00858725
Carpenter JL, Hoffman EP, Romanul FC, Kunkel LM, Rosales RK, Ma NS, Dasbach JJ, Rae JF, Moore FM, McAfee MB et al (1989) Feline muscular dystrophy with dystrophin deficiency. Am J Pathol 135:909–919
Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF (2011) Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39:e82. https://doi.org/10.1093/nar/gkr218
Chamova T, Guergueltcheva V, Raycheva M, Todorov T, Genova J, Bichev S, Bojinova V, Mitev V, Tournev I, Todorova A (2013) Association between loss of dp140 and cognitive impairment in duchenne and becker dystrophies. Balkan J Med Genet 16:21–30. https://doi.org/10.2478/bjmg-2013-0014
Chapman VM, Miller DR, Armstrong D, Caskey CT (1989) Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 86:1292–1296. https://doi.org/10.1073/pnas.86.4.1292
Chen Y, Zheng Y, Kang Y, Yang W, Niu Y, Guo X, Tu Z, Si C, Wang H, Xing R, Pu X, Yang SH, Li S, Ji W, Li XJ (2015) Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum Mol Genet 24:3764–3774. https://doi.org/10.1093/hmg/ddv120
Chetboul V, Carlos C, Blot S, Thibaud JL, Escriou C, Tissier R, Retortillo JL, Pouchelon JL (2004) Tissue Doppler assessment of diastolic and systolic alterations of radial and longitudinal left ventricular motions in Golden Retrievers during the preclinical phase of cardiomyopathy associated with muscular dystrophy. Am J Vet Res 65:1335–1341. https://doi.org/10.2460/ajvr.2004.65.1335
Cooper BJ, Winand NJ, Stedman H, Valentine BA, Hoffman EP, Kunkel LM, Scott MO, Fischbeck KH, Kornegay JN, Avery RJ et al (1988) The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334:154–156. https://doi.org/10.1038/334154a0
Cotton S, Voudouris NJ, Greenwood KM (2001) Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. Dev Med Child Neurol 43:497–501. https://doi.org/10.1017/s0012162201000913
Cox GA, Phelps SF, Chapman VM, Chamberlain JS (1993) New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat Genet 4:87–93. https://doi.org/10.1038/ng0593-87
Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90:717–727. https://doi.org/10.1016/s0092-8674(00)80532-2
Doorenweerd N, Straathof CS, Dumas EM, Spitali P, Ginjaar IB, Wokke BH, Schrans DG, van den Bergen JC, van Zwet EW, Webb A, van Buchem MA, Verschuuren JJ, Hendriksen JG, Niks EH, Kan HE (2014) Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy. Ann Neurol 76:403–411. https://doi.org/10.1002/ana.24222
Dowling JJ (2016) Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat Rev Neurol 12:675–676. https://doi.org/10.1038/nrneurol.2016.180
D’Souza VN, Nguyen TM, Morris GE, Karges W, Pillers DA, Ray PN (1995) A novel dystrophin isoform is required for normal retinal electrophysiology. Hum Mol Genet 4:837–842. https://doi.org/10.1093/hmg/4.5.837
Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K (2007) Managing Duchenne muscular dystrophy–the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17:470–475. https://doi.org/10.1016/j.nmd.2007.03.002
Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K, Yokota T (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45–55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. https://doi.org/10.1038/mtna.2014.76
Egorova TV, Zotova ED, Reshetov DA, Polikarpova AV, Vassilieva SG, Vlodavets DV, Gavrilov AA, Ulianov SV, Buchman VL, Deykin AV (2019) CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene. Dis Model Mech 12:dmm037655. https://doi.org/10.1242/dmm.037655
El Mathari B, Sene A, Charles-Messance H, Vacca O, Guillonneau X, Grepin C, Sennlaub F, Sahel JA, Rendon A, Tadayoni R (2015) Dystrophin Dp71 gene deletion induces retinal vascular inflammation and capillary degeneration. Hum Mol Genet 24:3939–3947. https://doi.org/10.1093/hmg/ddv132
Fan Z, Wang J, Ahn M, Shiloh-Malawsky Y, Chahin N, Elmore S, Bagnell CR Jr, Wilber K, An H, Lin W, Zhu H, Styner M, Kornegay JN (2014) Characteristics of magnetic resonance imaging biomarkers in a natural history study of golden retriever muscular dystrophy. Neuromuscul Disord 24:178–191. https://doi.org/10.1016/j.nmd.2013.10.005
Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD (2006) Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8:207–216. https://doi.org/10.1002/jgm.838
Fujimoto T, Itoh K, Yaoi T, Fushiki S (2014) Somatodendritic and excitatory postsynaptic distribution of neuron-type dystrophin isoform, Dp40, in hippocampal neurons. Biochem Biophys Res Commun 452:79–84. https://doi.org/10.1016/j.bbrc.2014.08.064
Gaschen FP, Hoffman EP, Gorospe JR, Uhl EW, Senior DF, Cardinet GH 3rd, Pearce LK (1992) Dystrophin deficiency causes lethal muscle hypertrophy in cats. J Neurol Sci 110:149–159. https://doi.org/10.1016/0022-510x(92)90022-d
Giacomotto J, Ségalat L (2010) High-throughput screening and small animal models, where are we? Br J Pharmacol 160:204–216. https://doi.org/10.1111/j.1476-5381.2010.00725.x
Gibbs EM, Horstick EJ, Dowling JJ (2013) Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies. FEBS J 280:4187–4197. https://doi.org/10.1111/febs.12412
Gieseler K, Grisoni K, Ségalat L (2000) Genetic suppression of phenotypes arising from mutations in dystrophin-related genes in Caenorhabditis elegans. Curr Biol 10:1092–1097. https://doi.org/10.1016/s0960-9822(00)00691-6
Gilbert R, Nalbantoglu J, Petrof BJ, Ebihara S, Guibinga GH, Tinsley JM, Kamen A, Massie B, Davies KE, Karpati G (1999) Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther 10:1299–1310. https://doi.org/10.1089/10430349950017987
Górecki DC, Monaco AP, Derry JM, Walker AP, Barnard EA, Barnard PJ (1992) Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet 1:505–510. https://doi.org/10.1093/hmg/1.7.505
Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90:729–738. https://doi.org/10.1016/s0092-8674(00)80533-4
Grosso S, Perrone S, Longini M, Bruno C, Minetti C, Gazzolo D, Balestri P, Buonocore G (2007) Isoprostanes in dystrophinopathy: Evidence of increased oxidative stress. Brain Dev 30:391–395. https://doi.org/10.1016/j.braindev.2007.11.005
Guo C, Willem M, Werner A, Raivich G, Emerson M, Neyses L, Mayer U (2006) Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet 15:989–998. https://doi.org/10.1093/hmg/ddl018
Guyon JR, Goswami J, Jun SJ, Thorne M, Howell M, Pusack T, Kawahara G, Steffen LS, Galdzicki M, Kunkel LM (2009) Genetic isolation and characterization of a splicing mutant of zebrafish dystrophin. Hum Mol Genet 18:202–211. https://doi.org/10.1093/hmg/ddn337
Hauser E, Höger H, Bittner R, Widhalm K, Herkner K, Lubec G (1995) Oxyradical damage and mitochondrial enzyme activities in the mdx mouse. Neuropediatrics 26:260–262. https://doi.org/10.1055/s-2007-979768
Haycock JW, MacNeil S, Jones P, Harris JB, Mantle D (1996) Oxidative damage to muscle protein in Duchenne muscular dystrophy. NeuroReport 8:357–361. https://doi.org/10.1097/00001756-199612200-00070
Howard PL, Dally GY, Ditta SD, Austin RC, Worton RG, Klamut HJ, Ray PN (1999) Dystrophin isoforms DP71 and DP427 have distinct roles in myogenic cells. Muscle Nerve 22:16–27. https://doi.org/10.1002/(sici)1097-4598(199901)22:1%3c16::aid-mus5%3e3.0.co;2-r
Howe K, Clark MD, Torroja CF et al (2013) The zebrafish reference genome sequence and its relationship to the human genome. Nature 496:498–503. https://doi.org/10.1038/nature12111
Howell JM, Fletcher S, Kakulas BA, O’Hara M, Lochmuller H, Karpati G (1997) Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. Neuromuscul Disord 7:325–328. https://doi.org/10.1016/s0960-8966(97)00057-6
Howell JM, Lochmüller H, O’Hara A, Fletcher S, Kakulas BA, Massie B, Nalbantoglu J, Karpati G (1998) High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum Gene Ther 9:629–634. https://doi.org/10.1089/hum.1998.9.5-629
Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS (1996) Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 5:1149–1153. https://doi.org/10.1093/hmg/5.8.1149
Janssen PM, Hiranandani N, Mays TA, Rafael-Fortney JA (2005) Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 289:H2373–H2378. https://doi.org/10.1152/ajpheart.00448.2005
Kawahara G, Karpf JA, Myers JA, Alexander MS, Guyon JR, Kunkel LM (2011) Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 108:5331–5336. https://doi.org/10.1073/pnas.1102116108
Keep NH (2000) Structural comparison of actin binding in utrophin and dystrophin. Neurological Sci 21:929–937. https://doi.org/10.1007/s100720070006
Kim K, Ryu SM, Kim ST, Baek G, Kim D, Lim K, Chung E, Kim S, Kim JS (2017) Highly efficient RNA-guided base editing in mouse embryos. Nat Biotechnol 35:435–437. https://doi.org/10.1038/nbt.3816
Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A, Krebs S, Kessler B, Zakhartchenko V, Kurome M, Kemter E, Nagashima H, Schoser B, Herbach N, Blum H, Wanke R, Aartsma-Rus A, Thirion C, Lochmüller H, Walter MC, Wolf E (2013) Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet 22:4368–4382. https://doi.org/10.1093/hmg/ddt287
Koenig M, Monaco AP, Kunkel LM (1988) The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53:219–228. https://doi.org/10.1016/0092-8674(88)90383-2
Koo T, Okada T, Athanasopoulos T, Foster H, Takeda S, Dickson G (2011) Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med 13:497–506. https://doi.org/10.1002/jgm.1602
Koo T, Lu-Nguyen NB, Malerba A, Kim E, Kim D, Cappellari O, Cho HY, Dickson G, Popplewell L, Kim JS (2018) Functional rescue of dystrophin deficiency in mice caused by frameshift mutations Using Campylobacter jejuni Cas9. Mol Ther 26:1529–1538. https://doi.org/10.1016/j.ymthe.2018.03.018
Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, Wang B, Qiao C, Howard JF Jr, Xiao X (2010) Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18:1501–1508. https://doi.org/10.1038/mt.2010.94
Kreipke RE, Kwon YV, Shcherbata HR, Ruohola-Baker H (2016) Drosophila melanogaster as a model of muscle degeneration disorders. Curr Top Dev Biol 121:83–109. https://doi.org/10.1016/bs.ctdb.2016.07.003
Lanfossi M, Cozzi F, Bugini D, Colombo S, Scarpa P, Morandi L, Galbiati S, Cornelio F, Pozza O, Mora M (1999) Development of muscle pathology in canine X-linked muscular dystrophy. I. Delayed postnatal maturation of affected and normal muscle as revealed by myosin isoform analysis and utrophin expression. Acta Neuropathol 97:127–138. https://doi.org/10.1007/s004010050965
Larcher T, Lafoux A, Tesson L, Remy S, Thepenier V, François V, Le Guiner C, Goubin H, Dutilleul M, Guigand L, Toumaniantz G, De Cian A, Boix C, Renaud JB, Cherel Y, Giovannangeli C, Concordet JP, Anegon I, Huchet C (2014) Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE 9:e110371. https://doi.org/10.1371/journal.pone.0110371
Lecroisey C, Ségalat L, Gieseler K (2007) The C. elegans dense body: anchoring and signaling structure of the muscle. J Muscle Res Cell Motil 28:79–87. https://doi.org/10.1007/s10974-007-9104-y
Lefaucheur JP, Pastoret C, Sebille A (1995) Phenotype of dystrophinopathy in old mdx mice. Anat Rec 242:70–76. https://doi.org/10.1002/ar.1092420109
Li D, Yue Y, Duan D (2008) Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am J Pathol 172:1332–1341. https://doi.org/10.2353/ajpath.2008.071042
Li D, Yue Y, Duan D (2010) Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. PLoS ONE 5:e15286. https://doi.org/10.1371/journal.pone.0015286
Lidov HG (1996) Dystrophin in the nervous system. Brain Pathol 6:63–77. https://doi.org/10.1111/j.1750-3639.1996.tb00783.x
Lim KRQ, Nguyen Q, Dzierlega K, Huang Y, Yokota T (2020) CRISPR-generated animal models of Duchenne muscular dystrophy. Genes (basel) 11:342. https://doi.org/10.3390/genes11030342
Love DR, Hill DF, Dickson G, Spurr NK, Byth BC, Marsden RF, Walsh FS, Edwards YH, Davies KE (1989) An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339:55–58. https://doi.org/10.1038/339055a0
McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD (2006) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13:1373–1381. https://doi.org/10.1038/sj.gt.3302800
McGreevy JW, Hakim CH, McIntosh MA, Duan D (2015) Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech 8:195–213. https://doi.org/10.1242/dmm.018424
Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E (2016) Eteplirsen study group and telethon foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79:257–271. https://doi.org/10.1002/ana.24555
Mention K, Santos L, Harrison PT (2019) Gene and base editing as a therapeutic option for cystic fibrosis-learning from other diseases. Genes (basel) 10:387. https://doi.org/10.3390/genes10050387
Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G (2006) Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 168:918–926. https://doi.org/10.2353/ajpath.2006.050673
Milic Rasic V, Vojinovic D, Pesovic J, Mijalkovic G, Lukic V, Mladenovic J, Kosac A, Novakovic I, Maksimovic N, Romac S, Todorovic S, Savic Pavicevic D (2015) Intellectual ability in the duchenne muscular dystrophy and dystrophin gene mutation location. Balkan J Med Genet 17:25–35. https://doi.org/10.2478/bjmg-2014-0071
Min YL, Li H, Rodriguez-Caycedo C, Mireault AA, Huang J, Shelton JM, McAnally JR, Amoasii L, Mammen PPA, Bassel-Duby R, Olson EN (2019) CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci Adv 5:eaav4324. https://doi.org/10.1126/sciadv.aav4324
Nakamura A, Kobayashi M, Kuraoka M, Yuasa K, Yugeta N, Okada T, Takeda S (2013) Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in Duchenne muscular dystrophy dog. Sci Rep 3:2183. https://doi.org/10.1038/srep02183
Nakamura K, Fujii W, Tsuboi M, Tanihata J, Teramoto N, Takeuchi S, Naito K, Yamanouchi K, Nishihara M (2014) Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci Rep 4:5635. https://doi.org/10.1038/srep05635
Nguyen F, Cherel Y, Guigand L, Goubault-Leroux I, Wyers M (2002) Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies. J Comp Pathol 126:100–108. https://doi.org/10.1053/jcpa.2001.0526
Nichols B, Takeda S, Yokota T (2015) Nonmechanical Roles of Dystrophin and associated proteins in exercise, neuromuscular junctions, and brains. Brain Sci 5:275–298. https://doi.org/10.3390/brainsci5030275
Nikolenko NYu, Goncharova OV, Artemyeva SB, Achkasov EE, Litvinova EB (2014) Rehabilitation of children with progressive muscular dystrophy Duchenne. Rus Bull Perinatol Pediatr 4:28–31
Nudel U, Zuk D, Einat P, Zeelon E, Levy Z, Neuman S, Yaffe D (1989) Duchenne muscular dystrophy gene product is not identical in muscle and brain. Nature 337:76–78. https://doi.org/10.1038/337076a0
Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA (2015) Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6:6244. https://doi.org/10.1038/ncomms7244
Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, Rosaria Cecio M, Torre V, Luca DE, F, Picillo E, Paciello O, Piluso G, Nigro G, Politano L, (2012) Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol Myopathies Cardiomyopathies off J Mediterr Soc Myol 31:121–125
Pastoret C, Sebille A (1995) mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 129:97–105. https://doi.org/10.1016/0022-510x(94)00276-t
Peter AK, Cheng H, Ross RS, Knowlton KU, Chen J (2011) The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog Pediatr Cardiol 31:83–88. https://doi.org/10.1016/j.ppedcard.2011.02.003
Plantié E, Migocka-Patrzałek M, Daczewska M, Jagla K (2015) Model organisms in the fight against muscular dystrophy: lessons from drosophila and Zebrafish. Molecules 20:6237–6253. https://doi.org/10.3390/molecules20046237
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281–2308. https://doi.org/10.1038/nprot.2013.143
Rapaport D, Fuchs O, Nudel U, Yaffe D (1992) Expression of the Duchenne muscular dystrophy gene products in embryonic stem cells and their differentiated derivatives. J Biol Chem 267:21289–21292
Reinig AM, Mirzaei S, Berlau DJ (2017) Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies. Pharmacotherapy 37:492–499. https://doi.org/10.1002/phar.1909
Rice ML, Wong B, Horn PS, Yang MB (2018) Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients. J AAPOS off Publ Am Assoc Pediatric Ophthalmol Strabismus 22:192–196. https://doi.org/10.1016/j.jaapos.2018.01.017
Ricotti V, Mandy WP, Scoto M, Pane M, Deconinck N, Messina S, Mercuri E, Skuse DH, Muntoni F (2016) Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol 58:77–84. https://doi.org/10.1111/dmcn.12922
Roberts RG, Bobrow M (1998) Dystrophins in vertebrates and invertebrates. Hum Mol Genet 7:589–595. https://doi.org/10.1093/hmg/7.4.589
Rudnicki MA, Braun T, Hinuma S, Jaenisch R (1992) Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell 71:383–390. https://doi.org/10.1016/0092-8674(92)90508-a
Ryder-Cook AS, Sicinski P, Thomas K, Davies KE, Worton RG, Barnard EA, Darlison MG, Barnard PJ (1988) Localization of the mdx mutation within the mouse dystrophin gene. EMBO J 7:3017–3021
Sadoulet-Puccio HM, Rajala M, Kunkel LM (1997) Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. Proc Natl Acad Sci USA 94:12413–12418. https://doi.org/10.1073/pnas.94.23.12413
Sarig R, Mezger-Lallemand V, Gitelman I, Davis C, Fuchs O, Yaffe D, Nudel U (1999) Targeted inactivation of Dp71, the major non-muscle product of the DMD gene: differential activity of the Dp71 promoter during development. Hum Mol Genet 8:1–10. https://doi.org/10.1093/hmg/8.1.1
Schofield J, Houzelstein D, Davies K, Buckingham M, Edwards YH (1993) Expression of the dystrophin-related protein (utrophin) gene during mouse embryogenesis. Dev Dyn 198:254–264. https://doi.org/10.1002/aja.1001980403
Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, Hung WY, Constantinou CD, Dykstra MJ, Roses AD et al (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13:115–121. https://doi.org/10.1016/0888-7543(92)90210-j
Shelton GD, Engvall E (2005) Canine and feline models of human inherited muscle diseases. Neuromuscul Disord 15:127–138. https://doi.org/10.1016/j.nmd.2004.10.019
Shimatsu Y, Katagiri K, Furuta T, Nakura M, Tanioka Y, Yuasa K, Tomohiro M, Kornegay JN, Nonaka I, Takeda S (2003) Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52:93–97. https://doi.org/10.1538/expanim.52.93
Shimatsu Y, Yoshimura M, Yuasa K, Urasawa N, Tomohiro M, Nakura M, Tanigawa M, Nakamura A, Takeda S (2005) Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 24:145–154
Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, Zhang K, Terjung RL, Duan D (2013) Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther 21:750–757. https://doi.org/10.1038/mt.2012.283
Shoji E, Sakurai H, Nishino T, Nakahata T, Heike T, Awaya T, Fujii N, Manabe Y, Matsuo M, Sehara-Fujisawa A (2015) Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. Sci Rep 5:12831. https://doi.org/10.1038/srep12831
Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244:1578–1580. https://doi.org/10.1126/science.2662404
Simonds AK, Muntoni F, Heather S, Fielding S (1998) Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 53:949–952. https://doi.org/10.1136/thx.53.11.949
Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM (1991) The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352:536–539. https://doi.org/10.1038/352536a0
Stein CA (2016) Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice. Mol Ther 24:1884–1885. https://doi.org/10.1038/mt.2016.188
Sui T, Lau YS, Liu D, Liu T, Xu L, Gao Y, Lai L, Li Z, Han R (2018) A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9. Dis Model Mech 11:dmm032201. https://doi.org/10.1242/dmm.032201
Takeda S (2009) Exon skipping therapy for Duchenne muscular dystrophy by using antisense morpholino. Rinsho Shinkeigaku 49:856–858. https://doi.org/10.5692/clinicalneurol.49.856
Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC, Knight AE, Kendrick-Jones J, Suthers GK, Love DR et al (1992) Primary structure of dystrophin-related protein. Nature 360:591–593. https://doi.org/10.1038/360591a0
Tozawa T, Itoh K, Yaoi T, Tando S, Umekage M, Dai H, Hosoi H, Fushiki S (2012) The shortest isoform of dystrophin (Dp40) interacts with a group of presynaptic proteins to form a presumptive novel complex in the mouse brain. Mol Neurobiol 45:287–297. https://doi.org/10.1007/s12035-012-8233-5
Vaillend C, Ungerer A (1999) Behavioral characterization of mdx3cv mice deficient in C-terminal dystrophins. Neuromuscul Disord 9:296–304. https://doi.org/10.1016/s0960-8966(99)00029-2
Valentine BA, Cooper BJ (1991) Canine X-linked muscular dystrophy: selective involvement of muscles in neonatal dogs. Neuromuscul Disord 1:31–38. https://doi.org/10.1016/0960-8966(91)90040-y
Valentine BA, Cooper BJ, de Lahunta A, O’Quinn R, Blue JT (1988) Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 88:69–81. https://doi.org/10.1016/0022-510x(88)90206-7
Van Erp C, Loch D, Laws N, Trebbin A, Hoey AJ (2010) Timeline of cardiac dystrophy in 3–18-month-old MDX mice. Muscle Nerve 42:504–513. https://doi.org/10.1002/mus.21716
van Putten M, Hulsker M, Young C, Nadarajah VD, Heemskerk H, van der Weerd L, ‘tHoen PA, van Ommen GJ, Aartsma-Rus AM (2013) Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J 27:2484–2495. https://doi.org/10.1096/fj.12-224170
Veltrop M, van Vliet L, Hulsker M, Claassens J, Brouwers C, Breukel C, van der Kaa J, Linssen MM, den Dunnen JT, Verbeek S, Aartsma-Rus A, van Putten M (2018) A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLoS ONE 13:e0193289. https://doi.org/10.1371/journal.pone.0193289
Walmsley GL, Arechavala-Gomeza V, Fernandez-Fuente M, Burke MM, Nagel N, Holder A, Stanley R, Chandler K, Marks SL, Muntoni F, Shelton GD, Piercy RJ (2010) A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS ONE 5:e8647. https://doi.org/10.1371/journal.pone.0008647
Waugh TA, Horstick E, Hur J, Jackson SW, Davidson AE, Li X, Dowling JJ (2014) Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy. Hum Mol Genet 23:4651–4662. https://doi.org/10.1093/hmg/ddu185
Winand NJ, Edwards M, Pradhan D, Berian CA, Cooper BJ (1994) Deletion of the dystrophin muscle promoter in feline muscular dystrophy. Neuromuscul Disord 4:433–445. https://doi.org/10.1016/0960-8966(94)90082-5
Wong TWY, Ahmed A, Yang G, Maino E, Steiman S, Hyatt E, Chan P, Lindsay K, Wong N, Golebiowski D, Schneider J, Delgado-Olguín P, Ivakine EA, Cohn RD (2020) A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy. Dis Model Mech 13:dmm045369. https://doi.org/10.1242/dmm.045369
Xu L, Park KH, Zhao L, Xu J, El Refaey M, Gao Y, Zhu H, Ma J, Han R (2016) CRISPR-mediated genome editing restores dystrophin expression and function in mdx Mice. Mol Ther 24:564–569. https://doi.org/10.1038/mt.2015.192
Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667–676. https://doi.org/10.1002/ana.21627
Young CS, Mokhonova E, Quinonez M, Pyle AD, Spencer MJ (2017) Creation of a novel humanized dystrophic mouse model of duchenne muscular dystrophy and application of a CRISPR/Cas9 gene editing therapy. J Neuromuscul Dis 4:139–145. https://doi.org/10.3233/JND-170218
Yu HH, Zhao H, Qing YB, Pan WR, Jia BY, Zhao HY, Huang XX, Wei HJ (2016) Porcine Zygote Injection with Cas9/sgRNA Results in DMD-Modified Pig with Muscle Dystrophy. Int J Mol Sci 17:1668. https://doi.org/10.3390/ijms17101668
Yucel N, Chang AC, Day JW, Rosenthal N, Blau HM (2020) Humanizing the mdx mouse model of DMD: the long and the short of it. NPJ Regen Med 3:4. https://doi.org/10.1038/s41536-018-0045-4
Zhan H, Stanciauskas R, Stigloher C, Dizon KK, Jospin M, Bessereau JL, Pinaud F (2014) In vivo single-molecule imaging identifies altered dynamics of calcium channels in dystrophin-mutant C. elegans. Nat Commun 5:4974. https://doi.org/10.1038/ncomms5974
Zhdanova EB, Kharmalov DA, Belousova ED (2011) Somatic Disorders in Duchenne Muscular Dystrophy. Rus Bull Perinatol Pediatrics 5:46–50
Funding
The work was carried out as part of the state assignment from the Ministry of Education and Science of Russia for the Research Centre for Medical Genetics.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zaynitdinova, M.I., Lavrov, A.V. & Smirnikhina, S.A. Animal models for researching approaches to therapy of Duchenne muscular dystrophy. Transgenic Res 30, 709–725 (2021). https://doi.org/10.1007/s11248-021-00278-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11248-021-00278-3